Serum 25-hydroxyvitamin D levels modulate the acute-phase response associated with the first nitrogen-containing bisphosphonate infusion

Abstract

The acute-phase response (APR) is the most frequent side effect after the first dose of intravenous nitrogen-containing bisphosphonates (N-BPs). It has been demonstrated in vitro that N-BPs stimulate gd T-cell proliferation and production of cytokines and that vitamin D is able to modulate them. Therefore, we have studied the relationship between bone metabolism parameters, particularly for 25-hydroxyvitamin D [25(OH)D], and APR in patients treated with 5 mg zoledronic acid intravenously. Ninety N-BP-naive osteoporotic women (63.7 AE 10.6 years of age) were stratified for the occurrence of APR (APR þ ) or not (APR -) and quantified by body temperature and

Serum 25-hydroxyvitamin D level and acute-phase reaction following initial intravenous bisphosphonate

“…The two cycles then were combined for multivariate analysis. The correlation between serum 25(OH)D level and sum of pain scales after infusion remained significant even after adjusting for confounding variables such as treatment arms (placebo versus Atorvastatin), body mass index (BMI), parathyr-LETTER TO THE EDITOR J JBMR We thus believe that our data support the findings reported by Bertoldo and colleagues (5) and can be extrapolated to children as well. We believe that low serum vitamin D is a risk factor for APR and thus would recommend that children be replete with vitamin D prior to giving bisphosphonate therapy until we have a better understanding of the underlying mechanism of APR following intravenous bisphosphonate therapy.…”

“…(3,4) However in a double-blind, randomized, crossover, placebo-controlled study in 12 children, treatment with Atorvastatin did not alleviate the APR. (1) Recently, Bertoldo and colleagues (5) reported an association between serum 25-hydroxyvitamin D [25(OH)D] level and APR after bisphosphonate infusion. In essence, lower levels of vitamin D were associated more frequently with APR, and vice versa.…”

“…In essence, lower levels of vitamin D were associated more frequently with APR, and vice versa. (5) We report the results of reanalysis of our data in order to evaluate a possible association between serum 25(OH)D level and APR following initial intravenous bisphosphonate treatment in children.…”

Comparison of intravenous and intramuscular neridronate regimens for the treatment of paget disease of bone

“…Interestingly, we also observed lower vitamin D levels in patients reporting acutephase reaction, which is consistent with findings from a recent study in osteoporotic women undergoing zoledronate treatment. (27) This suggest that acute-phase response following amino-bisphophonate treatment may be related to vitamin D status, possibly through direct effects on gd T cells, the subpopulations of T cells mainly involved in acute-phase reaction. (28) Moreover, in our population of PDB patients, 25(OH)D levels also were associated with the response to neridronate treatment.…”

Once-yearly zoledronic acid 5 mg therapy for osteoporosis: a focus on a patient

“…По данным F. Bertoldo и соавт. [81], у пациентов с не-достатком и дефицитом витамина D острые нежелательные явления встречались чаще, чем у больных с нормальным уровнем витамина D. Это может быть одним из объяснений более низкой частоты постдозных симптомов в исследова-нии HORIZON-RFT, чем в исследовании HORIZON-PFT. При уровне витамина D ≤15 нг/мл пациенты в исследовании HORIZON-RFT получали высокую дозу витамина D3 или D2 (50 000-125 000 МЕ перорально или внутримышечно) в тече-ние 14 дней до первого введения золедроновой кислоты [49].…”